UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): September 18, 2014 (September 13, 2014)

 

 

Neuralstem, Inc.

(Exact name of registrant as specified in Charter)

 

Delaware 000-1357459

52-2007292

(State or other jurisdiction of

incorporation or organization)

 (Commission File No.) (IRS Employee Identification No.)

 

20271 Goldenrod Lane, 2nd Floor, Germantown, Maryland 20876

(Address of Principal Executive Offices)

 

(301) 366-4960

(Issuer Telephone number)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

Item 5.02.Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

 

On September 13, 2014, the compensation committee (“Committee”) of Neuralstem, Inc. (the “Company”) ratified an increase in salary for Dr. Karl Johe, the Company’s Chief Scientific Officer. The Committee set Dr. Johe’s salary at $750,000 effective January 1, 2014. No other provisions of Dr. Johe’s employment agreement were changed.

 

 

Item 9.01Financial Statement and Exhibits.

 

Exhibit Number   Description
     
10.01   Form of Employment Agreement Amendment of Dr. Karl Johe
     

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

  NEURALSTEM, INC
       
  By:   /s/ I. Richard Garr  
     

I. Richard Garr

Chief Executive Officer

 

Dated: September 18, 2014

 

 

 

 

 

 

 

 
 

 

EXHIBITS

 

Exhibit

Number

 Description
     
10.01   Form of Employment Agreement Amendment of Dr. Karl Johe